Table 2.
Types of AEs in patients with HIV and concomitant CRC according to antiviral regimens (n = 66)
| AEs | DTG/3TC/TDF (group I) n = 20 | DTG/ABT (group II) n = 24 | BIC/TAF/FTC (group III) n = 22 | P value | |||
|---|---|---|---|---|---|---|---|
| Any grade | grade 3-5 | Any grade | Grade 3-5 | Any grade | Grade 3-5 | ||
| Neutropenia | 19 | 1 | 21 | 1 | 16 | 1 | 0.129 |
| Anemia | 4 | 0 | 3 | 1 | 7 | 0 | 0.284 |
| Thrombocytopenia | 2 | 0 | 1 | 0 | 1 | 0 | 0.672 |
| Peripheral neurotoxicity | 13 | 0 | 11 | 0 | 11 | 0 | 0.421 |
| Fever | 1 | 0 | 1 | 0 | 0 | 0 | – |
| Infection | 0 | 0 | 0 | 0 | 1 | 0 | – |
| Hypersensitivity | 0 | 0 | 1 | 0 | 0 | 0 | – |
| Liver function damage | 0 | 0 | 1 | 0 | 3 | 0 | – |
| Renal Impairment | 1 | 0 | 1 | 0 | 0 | 0 | – |
| Nausea | 20 | 1 | 24 | 0 | 22 | 1 | – |
| Vomiting | 2 | 1 | 2 | 0 | 3 | 0 | 0.884 |
| Diarrhea | 0 | 0 | 0 | 0 | 1 | 0 | – |
| Impaired cardiac function | 0 | 0 | 2 | 0 | 0 | 0 | – |
AEs = Adverse events
CRC = Colorectal cancer
DTG/3TC/TDF = dolutegravir/lamivudine/tenofovir
DTG/ABT = dolutegravir/albuvirtide
BIC/TAF/FTC = bictegravir/tenofovir alafenamide/emtricitabine
P value meant statistical difference of AEs in any grade among the three groups